SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-053971
Filing Date
2023-07-03
Accepted
2023-07-03 13:22:44
Documents
7
Period of Report
2023-07-03

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea181301-6k_nlspharma.htm 6-K 15743
2 PRESS RELEASE TITLED: "NLS PHARMACEUTICS RELEASES THE RESULTS OF ITS ANNUAL GENE ea181301ex99-1_nlspharma.htm EX-99.1 6765
3 PRESS RELEASE TITLED: "NLS PHARMACEUTICS COMPANY UPDATE AND WEBCAST TODAY POSTPO ea181301ex99-2_nlspharma.htm EX-99.2 7715
4 PRESS RELEASE TITLED: "NLS PHARMACEUTICS TO PROCEED WITH PHASE 3 CLINICAL PROGRA ea181301ex99-3_nlspharma.htm EX-99.3 15732
5 GRAPHIC ex99-1_001.jpg GRAPHIC 5536
6 GRAPHIC ex99-2_001.jpg GRAPHIC 19670
7 GRAPHIC ex99-3_001.jpg GRAPHIC 19670
  Complete submission text file 0001213900-23-053971.txt   109193
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 231064474
SIC: 2834 Pharmaceutical Preparations